간염 검사/진단 시장

출판: MarketsandMarkets(마켓츠앤드마켓츠)출판년월:2021년11월

・질병 유형(B형 간염, C형 간염, 기타 간염), 기술(ELISA, RDT, PCR, INAAT), 최종 사용자(병원, 진단 연구소, 혈액 은행), 지역별 – 2026년까지의 세계 예측

Hepatitis Testing/Diagnosis Market by Disease Type (Hepatitis B, Hepatitis C, Other Hepatitis), Technology (ELISA, RDT, PCR, INAAT), End User (Hospitals, Diagnostic Laboratories, Blood Banks), and Region – Global Forecast to 2026

폐이지수 175
도표수 204
구성 영문조사보고서
가격표

리포트목차보기    견적・문의・의뢰로 이동    구입안내

SAMPLE Request

 

 

The global hepatitis testing market is projected to reach USD 3.6 billion by 2026 from USD 2.8 billion in 2021, at a CAGR of 4.7% during the forecast period. The growth of the global hepatitis testing market is being driven by factors such as the high burden of hepatitis, increasing blood transfusion and donations, benefits of POC instruments and kits, and awareness initiatives on hepatitis.
세계 간염 검사 시장은 예측 기간 동안 4.7%의 CAGR로 2021년 28억 달러에서 2026년 36억 달러에 이를 것으로 예상됩니다. 글로벌 간염 테스트 시장의 성장은 간염에 대한 높은 부담, 수혈 및 기부 증가, POC 기기 및 키트의 이점, 간염에 대한 인식 이니셔티브와 같은 요인에 의해 주도되고 있습니다.
High cost of nucleic acid tests, lack of mandates for nucleic acid tests in developing countries and unfavorable reimbursement scenarios are expected to restrain hepatitis market growth. Emerging markets, rising technological advancements in molecular diagnostics, and growth in the biotechnology and biopharmaceutical industries are expected to offer strong growth opportunities for players in the market. In contrast, changing regulatory landscape, opertationsla barriers and shortage of skilled professionals may challenge market growth to a certain extent. The hepatitis testing market is segmented based on disease type, technology, end user, and region.

“Hepatitis B segment is expected to dominate the market during the forecast period.”

Based on disease type, the hepatitis testing market is segmented into hepatitis B, hepatitis C, and other hepatitis diseases (hepatitis A, D, and E). The hepatitis B segment accounted for the largest share of the hepatitis testing market in 2020. Factors such as the rising prevalence of hepatitis B, availability of a large number of hepatitis B diagnostic tests, and the increasing adoption of nucleic acid tests for HBV diagnosis are driving the growth of this market segment.

“ELISA segment holds highest market share during the forecast period.”

Based on technology, the hepatitis testing market is segmented into enzyme-linked immunosorbent assay (ELISA), rapid diagnostic tests, polymerase chain reaction (PCR), isothermal nucleic acid amplification technology (INAAT), and other technologies (such as sequencing, mass spectrometry, and western blotting). The ELISA segment accounted for the largest share of the hepatitis testing market in 2020. The large share of this segment can primarily be attributed to the wide acceptance of this test in clinical practices to diagnose hepatitis.

“Hospital & Diagnostic Laboratories segment to dominate the market during the forecast period.”

Based on end user, the hepatitis testing market is segmented into hospital & diagnostic laboratories, blood banks, and other end users (academic & government research institutes, nursing homes, and home care settings). In 2020, the hospital & diagnostic laboratories segment accounted for the largest share of the hepatitis testing market. The large share of this segment can be attributed to the large number of hepatitis diagnostic tests carried out in hospitals.

“North America will dominate the market during the forecast period.”

The global hepatitis testing market is segmented into North America (the US and Canada), Europe (Germany, the UK, and the Rest of Europe), Asia Pacific, and Rest of the World. In 2020, North America dominates the global market, and this trend is expected to continue during the forecast period. The large share and high growth of this region can be attributed to the rising prevalence of hepatitis and increased research and clinical trials for hepatitis testing in the US.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type -Tier 1: 32%,Tier 2: 42% and Tier 26%
• By Designation – C-level:23%, D-level:35%, and Others:42%
• By Region – North America:39%, Europe:25%, Asia Pacific:26%, and Rest of the World: 10%

List of Companies Profiled in the Report
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Abbott Laboratories (US)
• Siemens Healthineers AG (Germany)
• Bio-Rad Laboratories, Inc. (US)
• Danaher Corporation (US)
• QIAGEN (Netherlands)
• bioMérieux SA (France)
• DiaSorin S.P.A. (Italy)
• Ortho Clinical Diagnostics (US)
• MedMira Inc. (Canada)
• Fujirebio US, Inc. (Japan)
• Grifols, S.A. (Spain)
• Orasure Technologies (US)
• GenMark Diagnostics Inc. (US)
• Vela Diagnostics (Singapore)
• Epitope Diagnostics (US)
• Trivitron Healthcare (India)
• Meril Life Sciences Pvt. Ltd. (India)
• geneOmbio Technologies Pvt. Ltd. (India)
• Molbio Diagnostics Pvt. Ltd. (India)

Research Coverage:
This report provides a detailed picture of the global hepatitis testing market. It aims at estimating the size and future growth potential of the market across different segments, such as disease type, technology, end user and region. The report also analyzes factors (such as drivers, restraints,opportunities and challenges) affecting market growth. It evaluates the opportunities in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total hepatitis testing market. The report forecasts the revenue of the market segments with respect to four major regions.

Reasons to Buy the Report:
The report provides insights on the following pointers:
• Market Penetration: Comprehensive information on hepatitis testing offered by the top 20 players in the hepatitis testing market. The report analyses the hepatitis testing market by disease type, technology, end user and region.

• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various hepatitis testing across key geographic regions.

• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the hepatitis testing market.

• Competitive Assessment: In-depth assessment of market ranking and strategies of the leading players in the hepatitis testing market.


목차

1 INTRODUCTION 25
1.1 OBJECTIVES OF THE STUDY 25
1.2 MARKET DEFINITION 25
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY 25
1.3 MARKET SCOPE 26
FIGURE 1 HEPATITIS TESTING MARKET SEGMENTATION 26
1.3.1 YEARS CONSIDERED FOR THE STUDY 26
1.4 CURRENCY 27
1.5 STAKEHOLDERS 27
1.6 SUMMARY OF CHANGES 28
2 RESEARCH METHODOLOGY 29
2.1 RESEARCH DATA 29
FIGURE 2 RESEARCH DESIGN 29
2.1.1 SECONDARY DATA 30
2.1.1.1 Secondary sources 30
2.1.2 PRIMARY DATA 31
FIGURE 3 PRIMARY SOURCES 32
2.1.2.1 Key industry insights 33
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,
DESIGNATION, AND REGION 33
2.2 MARKET SIZE ESTIMATION 34
FIGURE 5 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 34
2.2.1 GROWTH FORECAST 35
FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 35
FIGURE 7 TOP-DOWN APPROACH 36
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 36
FIGURE 8 DATA TRIANGULATION METHODOLOGY 37
2.4 MARKET SHARE ANALYSIS 37
2.5 ASSUMPTIONS FOR THE STUDY 37
2.5.1 COVID-19-SPECIFIC ASSUMPTIONS 38
2.6 LIMITATIONS 38
2.7 RISK ASSESSMENT 39
2.8 COVID-19 ECONOMIC ASSESSMENT 39
2.9 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO 39
FIGURE 9 CRITERIA IMPACTING THE GLOBAL ECONOMY 40
FIGURE 10 RECOVERY SCENARIO OF THE GLOBAL ECONOMY 41
3 EXECUTIVE SUMMARY 42
FIGURE 11 HEPATITIS TESTING MARKET, BY DISEASE TYPE,
2021 VS. 2026 (USD MILLION) 42
FIGURE 12 HEPATITIS TESTING MARKET, BY TECHNOLOGY,
2021 VS. 2026 (USD MILLION) 43
FIGURE 13 HEPATITIS TESTING MARKET, BY END USER, 2021 VS. 2026 (USD MILLION) 43
FIGURE 14 HEPATITIS TESTING MARKET, BY REGION, 2021 VS. 2026 (USD MILLION) 44
4 PREMIUM INSIGHTS 45
4.1 HEPATITIS TESTING MARKET OVERVIEW 45
FIGURE 15 HIGH BURDEN OF HEPATITIS TO DRIVE MARKET GROWTH 45
4.2 HEPATITIS TESTING MARKET, BY TECHNOLOGY (2021–2026) 45
FIGURE 16 RAPID DIAGNOSTIC TESTS SEGMENT TO REGISTER THE HIGHEST
CAGR DURING THE FORECAST PERIOD 45
4.3 NORTH AMERICA: HEPATITIS TESTING MARKET, BY DISEASE TYPE AND COUNTRY (2020) 46
FIGURE 17 THE US ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH
AMERICAN HEPATITIS TESTING MARKET IN 2020 46
4.4 HEPATITIS TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 47
FIGURE 18 ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH DURING
THE FORECAST PERIOD 47
5 MARKET OVERVIEW 48
5.1 INTRODUCTION 48
FIGURE 19 HEPATITIS TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND CHALLENGES 48
5.2 MARKET DYNAMICS 48
5.2.1 DRIVERS 48
5.2.1.1 High burden of hepatitis 48
TABLE 1 HEPATITIS PREVALENCE, BY REGION, 2019 (MILLION) 49
5.2.1.2 Increasing blood transfusion and donations 49
TABLE 2 AVERAGE PREVALENCE OF HEPATITIS INFECTION IN BLOOD DONATIONS,
BY INCOME GROUP 50
5.2.1.3 Benefits of POC instruments and kits 50
5.2.1.4 Awareness initiatives on hepatitis 50
5.2.2 RESTRAINTS 51
5.2.2.1 High cost of nucleic acid tests 51
5.2.2.2 Lack of mandates for nucleic acid tests in developing countries 51
5.2.2.3 Unfavorable reimbursement scenario 51
5.2.3 OPPORTUNITIES 51
5.2.3.1 Emerging markets 51
5.2.3.2 Rising technological advancements in molecular diagnostics 52
5.2.3.3 Growth in the biotechnology and biopharmaceutical industries 52

5.2.4 CHALLENGES 52
5.2.4.1 Changing regulatory landscape 52
5.2.4.2 Operational barriers 53
5.2.4.3 Shortage of skilled professionals 53
5.3 COVID-19 IMPACT ON THE HEPATITIS TESTING MARKET 53
6 HEPATITIS TESTING MARKET, BY DISEASE TYPE 55
6.1 INTRODUCTION 56
TABLE 3 HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2018–2020 (USD MILLION) 56
TABLE 4 HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2021–2026 (USD MILLION) 56
6.2 HEPATITIS B (HBV) 56
6.2.1 HEPATITIS B SEGMENT TO HOLD THE LARGEST MARKET SHARE DURING
THE FORECAST PERIOD 56
TABLE 5 HEPATITIS B CHRONIC INFECTIONS IN THE WESTERN PACIFIC REGION, 2019 57
TABLE 6 HEPATITIS B TESTING MARKET, BY REGION, 2018–2020 (USD MILLION) 57
TABLE 7 HEPATITIS B TESTING MARKET, BY REGION, 2021–2026 (USD MILLION) 57
TABLE 8 NORTH AMERICA: HEPATITIS B TESTING MARKET, BY COUNTRY,
2018–2020 (USD MILLION) 58
TABLE 9 NORTH AMERICA: HEPATITIS B TESTING MARKET, BY COUNTRY,
2021–2026 (USD MILLION) 58
TABLE 10 EUROPE: HEPATITIS B TESTING MARKET, BY COUNTRY,
2018–2020 (USD MILLION) 58
TABLE 11 EUROPE: HEPATITIS B TESTING MARKET, BY COUNTRY,
2021–2026 (USD MILLION) 59
6.3 HEPATITIS C (HCV) 59
6.3.1 GOVERNMENT INITIATIVES FOR SUPPORTING HCV DIAGNOSIS
TO DRIVE MARKET GROWTH 59
TABLE 12 HEPATITIS C CHRONIC INFECTIONS IN THE WESTERN PACIFIC REGION, 2019 59
TABLE 13 HEPATITIS C TESTING MARKET, BY REGION, 2018–2020 (USD MILLION) 60
TABLE 14 HEPATITIS C TESTING MARKET, BY REGION, 2021–2026 (USD MILLION) 60
TABLE 15 NORTH AMERICA: HEPATITIS C TESTING MARKET, BY COUNTRY,
2018–2020 (USD MILLION) 60
TABLE 16 NORTH AMERICA: HEPATITIS C TESTING MARKET, BY COUNTRY,
2021–2026 (USD MILLION) 61
TABLE 17 EUROPE: HEPATITIS C TESTING MARKET, BY COUNTRY,
2018–2020 (USD MILLION) 61
TABLE 18 EUROPE: HEPATITIS C TESTING MARKET, BY COUNTRY,
2021–2026 (USD MILLION) 61
6.4 OTHER HEPATITIS DISEASES 62
TABLE 19 REP0RTED HEPATITIS A CASES IN THE US SINCE 2016 62
TABLE 20 OTHER HEPATITIS DISEASE TESTING MARKET, BY REGION,
2018–2020 (USD MILLION) 62
TABLE 21 OTHER HEPATITIS DISEASE TESTING MARKET, BY REGION,
2021–2026 (USD MILLION) 63
TABLE 22 NORTH AMERICA: OTHER HEPATITIS DISEASE TESTING MARKET,
BY COUNTRY, 2018–2020 (USD MILLION) 63
TABLE 23 NORTH AMERICA: OTHER HEPATITIS DISEASE TESTING MARKET,
BY COUNTRY, 2021–2026 (USD MILLION) 63
TABLE 24 EUROPE: OTHER HEPATITIS DISEASE TESTING MARKET, BY COUNTRY,
2018–2020 (USD MILLION) 64
TABLE 25 EUROPE: OTHER HEPATITIS DISEASE TESTING MARKET, BY COUNTRY,
2021–2026 (USD MILLION) 64
7 HEPATITIS TESTING MARKET, BY TECHNOLOGY 65
7.1 INTRODUCTION 66
TABLE 26 HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2018–2020 (USD MILLION) 66
TABLE 27 HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2021–2026 (USD MILLION) 66
7.2 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) 67
7.2.1 ELISA IS WIDELY USED FOR THE DETECTION OF HEPATITIS 67
TABLE 28 HEPATITIS TESTING MARKET FOR ELISA, BY REGION,
2018–2020 (USD MILLION) 67
TABLE 29 HEPATITIS TESTING MARKET FOR ELISA, BY REGION,
2021–2026 (USD MILLION) 68
TABLE 30 NORTH AMERICA: HEPATITIS TESTING MARKET FOR ELISA, BY COUNTRY, 2018–2020 (USD MILLION) 68
TABLE 31 NORTH AMERICA: HEPATITIS TESTING MARKET FOR ELISA, BY COUNTRY, 2021–2026 (USD MILLION) 68
TABLE 32 EUROPE: HEPATITIS TESTING MARKET FOR ELISA, BY COUNTRY,
2018–2020 (USD MILLION) 69
TABLE 33 EUROPE: HEPATITIS TESTING MARKET FOR ELISA, BY COUNTRY,
2021–2026 (USD MILLION) 69
7.3 RAPID DIAGNOSTIC TESTS (RDT) 69
7.3.1 RAPID TESTS ARE HIGHLY USEFUL IN COUNTRIES WITH LIMITED ACCESSIBILITY TO SOPHISTICATED TECHNOLOGIES 69
TABLE 34 HEPATITIS TESTING MARKET FOR RAPID DIAGNOSTIC TESTS, BY REGION, 2018–2020 (USD MILLION) 70
TABLE 35 HEPATITIS TESTING MARKET FOR RAPID DIAGNOSTIC TESTS, BY REGION, 2021–2026 (USD MILLION) 70
TABLE 36 NORTH AMERICA: HEPATITIS TESTING MARKET FOR RAPID DIAGNOSTIC TESTS, BY COUNTRY, 2018–2020 (USD MILLION) 71
TABLE 37 NORTH AMERICA: HEPATITIS TESTING MARKET FOR RAPID DIAGNOSTIC TESTS, BY COUNTRY, 2021–2026 (USD MILLION) 71
TABLE 38 EUROPE: HEPATITIS TESTING MARKET FOR RAPID DIAGNOSTIC TESTS,
BY COUNTRY, 2018–2020 (USD MILLION) 71
TABLE 39 EUROPE: HEPATITIS TESTING MARKET FOR RAPID DIAGNOSTIC TESTS,
BY COUNTRY, 2021–2026 (USD MILLION) 72
7.4 POLYMERASE CHAIN REACTION (PCR) 72
7.4.1 PCR TECHNOLOGY IS USED IN CONFIRMATORY TESTS FOR
HEPATITIS DIAGNOSIS 72
TABLE 40 HEPATITIS TESTING MARKET FOR POLYMERASE CHAIN REACTION,
BY REGION, 2018–2020 (USD MILLION) 72
TABLE 41 HEPATITIS TESTING MARKET FOR POLYMERASE CHAIN REACTION,
BY REGION, 2021–2026 (USD MILLION) 73
TABLE 42 NORTH AMERICA: HEPATITIS TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2018–2020 (USD MILLION) 73
TABLE 43 NORTH AMERICA: HEPATITIS TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2021–2026 (USD MILLION) 73
TABLE 44 EUROPE: HEPATITIS TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2018–2020 (USD MILLION) 74
TABLE 45 EUROPE: HEPATITIS TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2021–2026 (USD MILLION) 74
7.5 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT) 74
7.5.1 COST-BENEFITS OF INAAT ARE DRIVING THE GROWTH OF THIS MARKET SEGMENT 74
TABLE 46 HEPATITIS TESTING MARKET FOR INAAT, BY REGION,
2018–2020 (USD MILLION) 75
TABLE 47 HEPATITIS TESTING MARKET FOR INAAT, BY REGION,
2021–2026 (USD MILLION) 75
TABLE 48 NORTH AMERICA: HEPATITIS TESTING MARKET FOR INAAT, BY COUNTRY, 2018–2020 (USD MILLION) 75
TABLE 49 NORTH AMERICA: HEPATITIS TESTING MARKET FOR INAAT, BY COUNTRY, 2021–2026 (USD MILLION) 76
TABLE 50 EUROPE: HEPATITIS TESTING MARKET FOR INAAT, BY COUNTRY,
2018–2020 (USD MILLION) 76
TABLE 51 EUROPE: HEPATITIS TESTING MARKET FOR INAAT, BY COUNTRY,
2021–2026 (USD MILLION) 76
7.6 OTHER TECHNOLOGIES 77
TABLE 52 HEPATITIS TESTING MARKET FOR OTHER TECHNOLOGIES, BY REGION,
2018–2020 (USD MILLION) 77
TABLE 53 HEPATITIS TESTING MARKET FOR OTHER TECHNOLOGIES, BY REGION,
2021–2026 (USD MILLION) 77
TABLE 54 NORTH AMERICA: HEPATITIS TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2018–2020 (USD MILLION) 78
TABLE 55 NORTH AMERICA: HEPATITIS TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2021–2026 (USD MILLION) 78
TABLE 56 EUROPE: HEPATITIS TESTING MARKET FOR OTHER TECHNOLOGIES,
BY COUNTRY, 2018–2020 (USD MILLION) 78
TABLE 57 EUROPE: HEPATITIS TESTING MARKET FOR OTHER TECHNOLOGIES,
BY COUNTRY, 2021–2026 (USD MILLION) 79
8 HEPATITIS TESTING MARKET, BY END USER 80
8.1 INTRODUCTION 81
TABLE 58 HEPATITIS TESTING MARKET, BY END USER, 2018–2020 (USD MILLION) 81
TABLE 59 HEPATITIS TESTING MARKET, BY END USER, 2021–2026 (USD MILLION) 81
8.2 HOSPITAL & DIAGNOSTIC LABORATORIES 81
8.2.1 HOSPITAL & DIAGNOSTIC LABORATORIES ARE THE LARGEST END USERS
OF HEPATITIS TESTING PRODUCTS 81
TABLE 60 HEPATITIS TESTING MARKET FOR HOSPITAL & DIAGNOSTIC LABORATORIES, BY REGION, 2018–2020 (USD MILLION) 82
TABLE 61 HEPATITIS TESTING MARKET FOR HOSPITAL & DIAGNOSTIC LABORATORIES, BY REGION, 2021–2026 (USD MILLION) 83
TABLE 62 NORTH AMERICA: HEPATITIS TESTING MARKET FOR HOSPITAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018–2020 (USD MILLION) 83
TABLE 63 NORTH AMERICA: HEPATITIS TESTING MARKET FOR HOSPITAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2021–2026 (USD MILLION) 83
TABLE 64 EUROPE: HEPATITIS TESTING MARKET FOR HOSPITAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018–2020 (USD MILLION) 84
TABLE 65 EUROPE: HEPATITIS TESTING MARKET FOR HOSPITAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2021–2026 (USD MILLION) 84
8.3 BLOOD BANKS 84
8.3.1 INCREASING NUMBER OF BLOOD DONATIONS TO DRIVE THE GROWTH
OF THIS MARKET SEGMENT 84
TABLE 66 HEPATITIS TESTING MARKET FOR BLOOD BANKS, BY REGION,
2018–2020 (USD MILLION) 85
TABLE 67 HEPATITIS TESTING MARKET FOR BLOOD BANKS, BY REGION,
2021–2026 (USD MILLION) 85
TABLE 68 NORTH AMERICA: HEPATITIS TESTING MARKET FOR BLOOD BANKS,
BY COUNTRY, 2018–2020 (USD MILLION) 85
TABLE 69 NORTH AMERICA: HEPATITIS TESTING MARKET FOR BLOOD BANKS,
BY COUNTRY, 2021–2026 (USD MILLION) 86
TABLE 70 EUROPE: HEPATITIS TESTING MARKET FOR BLOOD BANKS, BY COUNTRY, 2018–2020 (USD MILLION) 86
TABLE 71 EUROPE: HEPATITIS TESTING MARKET FOR BLOOD BANKS, BY COUNTRY, 2021–2026 (USD MILLION) 86
8.4 OTHER END USERS 87
TABLE 72 HEPATITIS TESTING MARKET FOR OTHER END USERS, BY REGION,
2018–2020 (USD MILLION) 87
TABLE 73 HEPATITIS TESTING MARKET FOR OTHER END USERS, BY REGION,
2021–2026 (USD MILLION) 87
TABLE 74 NORTH AMERICA: HEPATITIS TESTING MARKET FOR OTHER END USERS,
BY COUNTRY, 2018–2020 (USD MILLION) 87
TABLE 75 NORTH AMERICA: HEPATITIS TESTING MARKET FOR OTHER END USERS,
BY COUNTRY, 2021–2026 (USD MILLION) 88
TABLE 76 EUROPE: HEPATITIS TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2018–2020 (USD MILLION) 88
TABLE 77 EUROPE: HEPATITIS TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2026 (USD MILLION) 88
9 EPATITIS TESTING MARKET, BY REGION 89
9.1 INTRODUCTION 90
TABLE 78 GLOBAL: HEPATITIS TESTING MARKET, BY REGION,
2018–2020 (USD MILLION) 90
TABLE 79 GLOBAL: HEPATITIS TESTING MARKET, BY REGION,
2021–2026 (USD MILLION) 90
9.2 NORTH AMERICA 90
FIGURE 20 NORTH AMERICA: HEPATITIS TESTING MARKET SNAPSHOT 91
TABLE 80 NORTH AMERICA: HEPATITIS TESTING MARKET, BY COUNTRY,
2018–2020 (USD MILLION) 91
TABLE 81 NORTH AMERICA: HEPATITIS TESTING MARKET, BY COUNTRY,
2021–2026 (USD MILLION) 92
TABLE 82 NORTH AMERICA: HEPATITIS TESTING MARKET, BY DISEASE TYPE,
2018–2020 (USD MILLION) 92
TABLE 83 NORTH AMERICA: HEPATITIS TESTING MARKET, BY DISEASE TYPE,
2021–2026 (USD MILLION) 92
TABLE 84 NORTH AMERICA: HEPATITIS TESTING MARKET, BY TECHNOLOGY,
2018–2020 (USD MILLION) 93
TABLE 85 NORTH AMERICA: HEPATITIS TESTING MARKET, BY TECHNOLOGY,
2021–2026 (USD MILLION) 93
TABLE 86 NORTH AMERICA: HEPATITIS TESTING MARKET, BY END USER,
2018–2020 (USD MILLION) 93
TABLE 87 NORTH AMERICA: HEPATITIS TESTING MARKET, BY END USER,
2021–2026 (USD MILLION) 94
9.2.1 US 94
9.2.1.1 High healthcare expenditure to drive market growth in the US 94
TABLE 88 US: NUMBER OF HEPATITIS A CASES REPORTED, 2015 VS. 2019 94
TABLE 89 HEPATITIS A PREVALENCE RATE PER 100,000 POPULATION
IN THE US, 2013–2017 95
TABLE 90 US: KEY MACROINDICATORS 95
TABLE 91 US: HEPATITIS TESTING MARKET, BY DISEASE TYPE,
2018–2020 (USD MILLION) 96
TABLE 92 US: HEPATITIS TESTING MARKET, BY DISEASE TYPE,
2021–2026 (USD MILLION) 96
TABLE 93 US: HEPATITIS TESTING MARKET, BY TECHNOLOGY,
2018–2020 (USD MILLION) 96
TABLE 94 US: HEPATITIS TESTING MARKET, BY TECHNOLOGY,
2021–2026 (USD MILLION) 97
TABLE 95 US: HEPATITIS TESTING MARKET, BY END USER, 2018–2020 (USD MILLION) 97
TABLE 96 US: HEPATITIS TESTING MARKET, BY END USER, 2021–2026 (USD MILLION) 97
9.2.2 CANADA 98
9.2.2.1 Favorable government initiatives are expected to boost market growth in Canada 98
TABLE 97 CANADA: KEY MACROINDICATORS 98
TABLE 98 CANADA: HEPATITIS TESTING MARKET, BY DISEASE TYPE,
2018–2020 (USD MILLION) 99
TABLE 99 CANADA: HEPATITIS TESTING MARKET, BY DISEASE TYPE,
2021–2026 (USD MILLION) 99
TABLE 100 CANADA: HEPATITIS TESTING MARKET, BY TECHNOLOGY,
2018–2020 (USD MILLION) 99
TABLE 101 CANADA: HEPATITIS TESTING MARKET, BY TECHNOLOGY,
2021–2026 (USD MILLION) 100
TABLE 102 CANADA: HEPATITIS TESTING MARKET, BY END USER,
2018–2020 (USD MILLION) 100
TABLE 103 CANADA: HEPATITIS TESTING MARKET, BY END USER,
2021–2026 (USD MILLION) 100

9.3 EUROPE 101
TABLE 104 NUMBER OF HEPATITIS B CASES IN EUROPE, BY COUNTRY, 2014–2018 101
TABLE 105 EUROPE: HEPATITIS TESTING MARKET, BY COUNTRY,
2018–2020 (USD MILLION) 101
TABLE 106 EUROPE: HEPATITIS TESTING MARKET, BY COUNTRY,
2021–2026 (USD MILLION) 102
TABLE 107 EUROPE: HEPATITIS TESTING MARKET, BY DISEASE TYPE,
2018–2020 (USD MILLION) 102
TABLE 108 EUROPE: HEPATITIS TESTING MARKET, BY DISEASE TYPE,
2021–2026 (USD MILLION) 102
TABLE 109 EUROPE: HEPATITIS TESTING MARKET, BY TECHNOLOGY,
2018–2020 (USD MILLION) 103
TABLE 110 EUROPE: HEPATITIS TESTING MARKET, BY TECHNOLOGY,
2021–2026 (USD MILLION) 103
TABLE 111 EUROPE: HEPATITIS TESTING MARKET, BY END USER,
2018–2020 (USD MILLION) 103
TABLE 112 EUROPE: HEPATITIS TESTING MARKET, BY END USER,
2021–2026 (USD MILLION) 104
9.3.1 GERMANY 104
9.3.1.1 Increasing demand for advanced diagnostic technologies to drive market growth in Germany 104
TABLE 113 GERMANY: KEY MACROINDICATORS 104
TABLE 114 GERMANY: HEPATITIS TESTING MARKET, BY DISEASE TYPE,
2018–2020 (USD MILLION) 105
TABLE 115 GERMANY: HEPATITIS TESTING MARKET, BY DISEASE TYPE,
2021–2026 (USD MILLION) 105
TABLE 116 GERMANY: HEPATITIS TESTING MARKET, BY TECHNOLOGY,
2018–2020 (USD MILLION) 105
TABLE 117 GERMANY: HEPATITIS TESTING MARKET, BY TECHNOLOGY,
2021–2026 (USD MILLION) 106
TABLE 118 GERMANY: HEPATITIS TESTING MARKET, BY END USER,
2018–2020 (USD MILLION) 106
TABLE 119 GERMANY: HEPATITIS TESTING MARKET, BY END USER,
2021–2026 (USD MILLION) 106
9.3.2 UK 107
9.3.2.1 Increasing number of clinical laboratories to drive market
growth in the UK 107
TABLE 120 NUMBER OF HEPATITIS C CASES REPORTED IN ENGLAND AND
WALES, 2008–2018 107
TABLE 121 UK: KEY MACROINDICATORS 108
TABLE 122 UK: HEPATITIS TESTING MARKET, BY DISEASE TYPE,
2018–2020 (USD MILLION) 108
TABLE 123 UK: HEPATITIS TESTING MARKET, BY DISEASE TYPE,
2021–2026 (USD MILLION) 108
TABLE 124 UK: HEPATITIS TESTING MARKET, BY TECHNOLOGY,
2018–2020 (USD MILLION) 109
TABLE 125 UK: HEPATITIS TESTING MARKET, BY TECHNOLOGY,
2021–2026 (USD MILLION) 109
TABLE 126 UK: HEPATITIS TESTING MARKET, BY END USER, 2018–2020 (USD MILLION) 109
TABLE 127 UK: HEPATITIS TESTING MARKET, BY END USER, 2021–2026 (USD MILLION) 110
9.3.3 REST OF EUROPE 110
TABLE 128 ROE: HEALTHCARE EXPENDITURE, BY COUNTRY, 2010 VS. 2018 (% OF GDP) 111
TABLE 129 ROE: HEPATITIS TESTING MARKET, BY DISEASE TYPE,
2018–2020 (USD MILLION) 112
TABLE 130 ROE: HEPATITIS TESTING MARKET, BY DISEASE TYPE,
2021–2026 (USD MILLION) 112
TABLE 131 ROE: HEPATITIS TESTING MARKET, BY TECHNOLOGY,
2018–2020 (USD MILLION) 112
TABLE 132 ROE: HEPATITIS TESTING MARKET, BY TECHNOLOGY,
2021–2026 (USD MILLION) 113
TABLE 133 ROE: HEPATITIS TESTING MARKET, BY END USER,
2018–2020 (USD MILLION) 113
TABLE 134 ROE: HEPATITIS TESTING MARKET, BY END USER,
2021–2026 (USD MILLION) 113
9.4 ASIA PACIFIC 114
9.4.1 HIGH PREVALENCE OF HEPATITIS TO BOOST MARKET GROWTH 114
TABLE 135 ASIA PACIFIC: ESTIMATED PREVALENCE OF CHRONIC HBV AND HCV 114
TABLE 136 ASIA PACIFIC: COST COVERAGE FOR THE DIAGNOSIS OF CHRONIC
VIRAL HEPATITIS 114
FIGURE 21 ASIA PACIFIC: HEPATITIS TESTING MARKET SNAPSHOT 115
TABLE 137 CHINA: KEY MACROINDICATORS 116
TABLE 138 JAPAN: KEY MACROINDICATORS 116
TABLE 139 INDIA: KEY MACROINDICATORS 117
TABLE 140 ASIA PACIFIC: HEPATITIS TESTING MARKET, BY DISEASE TYPE,
2018–2020 (USD MILLION) 117
TABLE 141 ASIA PACIFIC: HEPATITIS TESTING MARKET, BY DISEASE TYPE,
2021–2026 (USD MILLION) 118
TABLE 142 ASIA PACIFIC: HEPATITIS TESTING MARKET, BY TECHNOLOGY,
2018–2020 (USD MILLION) 118
TABLE 143 ASIA PACIFIC: HEPATITIS TESTING MARKET, BY TECHNOLOGY,
2021–2026 (USD MILLION) 118
TABLE 144 ASIA PACIFIC: HEPATITIS TESTING MARKET, BY END USER,
2018–2020 (USD MILLION) 119
TABLE 145 ASIA PACIFIC: HEPATITIS TESTING MARKET, BY END USER,
2021–2026 (USD MILLION) 119
9.5 REST OF THE WORLD 119
9.5.1 LESS-STRINGENT REGULATIONS FOR DIAGNOSTIC PRODUCTS TO DRIVE MARKET GROWTH 119
TABLE 146 REST OF THE WORLD: HEPATITIS TESTING MARKET, BY DISEASE TYPE,
2018–2020 (USD MILLION) 120
TABLE 147 REST OF THE WORLD: HEPATITIS TESTING MARKET, BY DISEASE TYPE,
2021–2026 (USD MILLION) 121
TABLE 148 REST OF THE WORLD: HEPATITIS TESTING MARKET, BY TECHNOLOGY,
2018–2020 (USD MILLION) 121
TABLE 149 REST OF THE WORLD: HEPATITIS TESTING MARKET, BY TECHNOLOGY,
2021–2026 (USD MILLION) 121
TABLE 150 REST OF THE WORLD: HEPATITIS TESTING MARKET, BY END USER,
2018–2020 (USD MILLION) 122
TABLE 151 REST OF THE WORLD: HEPATITIS TESTING MARKET, BY END USER,
2021–2026 (USD MILLION) 122
10 COMPETITIVE LANDSCAPE 123
10.1 OVERVIEW 123
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 123
TABLE 152 OVERVIEW OF STRATEGIES ADOPTED BY KEY HEPATITIS TESTING
MARKET PLAYERS 123
10.3 MARKET SHARE ANALYSIS 124
FIGURE 22 HEPATITIS TESTING MARKET SHARE ANALYSIS, 2020 124
TABLE 153 HEPATITIS TESTING MARKET: DEGREE OF COMPETITION (2020) 125
10.4 COMPANY EVALUATION QUADRANT 126
10.4.1 STARS 126
10.4.2 EMERGING LEADERS 126
10.4.3 PERVASIVE PLAYERS 126
10.4.4 PARTICIPANTS 126
FIGURE 23 HEPATITIS TESTING MARKET: COMPANY EVALUATION QUADRANT (2020) 127
10.5 COMPANY EVALUATION QUADRANT: SMES/START-UPS 127
10.5.1 PROGRESSIVE COMPANIES 127
10.5.2 STARTING BLOCKS 128
10.5.3 RESPONSIVE COMPANIES 128
10.5.4 DYNAMIC COMPANIES 128
FIGURE 24 HEPATITIS TESTING MARKET: COMPANY EVALUATION QUADRANT
FOR SMES & START-UPS (2020) 128
10.6 COMPETITIVE SCENARIO 129
10.6.1 PRODUCT LAUNCHES & APPROVALS 129
TABLE 154 PRODUCT LAUNCHES & APPROVALS 129
10.6.2 DEALS 130
TABLE 155 DEALS 130
10.6.3 OTHER DEVELOPMENTS 130
TABLE 156 OTHER DEVELOPMENTS 130
10.7 COMPANY FOOTPRINT ANALYSIS 131
TABLE 157 TECHNOLOGY, DISEASE TYPE, AND REGIONAL FOOTPRINT OF COMPANIES 131
TABLE 158 TECHNOLOGY FOOTPRINT OF COMPANIES 132
TABLE 159 DISEASE TYPE FOOTPRINT OF COMPANIES 133
TABLE 160 REGIONAL FOOTPRINT OF COMPANIES 134

11 COMPANY PROFILE 135
11.1 KEY PLAYERS 135
(Business Overview, Products Offered, Recent Developments, Deals, MnM view, Key strengths/right to win, Strategic choices made, Weakness/competitive threats)*
11.1.1 ABBOTT LABORATORIES 135
TABLE 161 ABBOTT LABORATORIES: BUSINESS OVERVIEW 135
FIGURE 25 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2020) 136
11.1.2 F. HOFFMANN-LA ROCHE LTD. 139
TABLE 162 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW 139
FIGURE 26 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2020) 140
11.1.3 BIO-RAD LABORATORIES, INC. 143
TABLE 163 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 143
FIGURE 27 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2020) 144
11.1.4 SIEMENS HEALTHINEERS AG 146
TABLE 164 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW 146
FIGURE 28 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2020) 147
11.1.5 DIASORIN S.P.A 149
TABLE 165 DIASORIN S.P.A: BUSINESS OVERVIEW 149
FIGURE 29 DIASORIN S.P.A.: COMPANY SNAPSHOT (2020) 150
11.1.6 QIAGEN 153
TABLE 166 QIAGEN: BUSINESS OVERVIEW 153
FIGURE 30 QIAGEN: COMPANY SNAPSHOT (2020) 154
11.1.7 DANAHER CORPORATION 155
TABLE 167 DANAHER CORPORATION: BUSINESS OVERVIEW 155
FIGURE 31 DANAHER CORPORATION: COMPANY SNAPSHOT (2020) 156
11.1.8 GRIFOLS, S.A. 158
TABLE 168 GRIFOLS, S.A.: BUSINESS OVERVIEW 158
FIGURE 32 GRIFOLS, S.A.: COMPANY SNAPSHOT (2020) 159
11.1.9 BIOMÉRIEUX SA 160
TABLE 169 BIOMÉRIEUX SA: BUSINESS OVERVIEW 160
FIGURE 33 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2020) 161
11.1.10 ORTHO CLINICAL DIAGNOSTICS 162
TABLE 170 ORTHO CLINICAL DIAGNOSTICS: BUSINESS OVERVIEW 162
FIGURE 34 ORTHO CLINICAL DIAGNOSTICS: COMPANY SNAPSHOT (2020) 163
11.2 OTHER PLAYERS 164
11.2.1 FUJIREBIO US, INC. 164
11.2.2 ORASURE TECHNOLOGIES 165
11.2.3 EPITOPE DIAGNOSTICS 166
11.2.4 TRIVITRON HEALTHCARE 167
11.2.5 MERIL LIFE SCIENCES PVT. LTD. 168
11.2.6 GENMARK DIAGNOSTICS INC. 169
11.2.7 VELA DIAGNOSTICS 170
11.2.8 MOLBIO DIAGNOSTICS PVT. LTD. 171
11.2.9 GENEOMBIO TECHNOLOGIES PVT. LTD. 172
11.2.10 MEDMIRA INC. 173
*Details on Business Overview, Products Offered, Recent Developments, Deals, MnM view, Key strengths/right to win, Strategic choices made, Weakness/competitive threats might not be captured in case of unlisted companies.
12 APPENDIX 174
12.1 INSIGHTS FROM INDUSTRY EXPERTS 174
12.2 DISCUSSION GUIDE 175
12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 178
12.4 AVAILABLE CUSTOMIZATIONS 180
12.5 RELATED REPORTS 180
12.6 AUTHOR DETAILS 181


    • 리포트 제목은 자동으로 입력됩니다.
    • *항목은 필수항목입니다.

    의뢰분류*

    성함*

    회사명*

    부서명

    이메일*

    전화번호

    저희 사이트를 알게 된 경로를 가르쳐 주세요.

    문의 내용*

     

    ※개인정보보호정책은여기에서 확인 가능합니다。

    Email 문의도 받고 있습니다.
    아래 주소이며 죄송하지만 "(at)"을 "@"로 바꾸어 보내주시길 부탁드립니다.
    mooneui(at)chosareport-korea.com